company background image
CTSO logo

Cytosorbents NasdaqCM:CTSO Stock Report

Last Price

US$0.95

Market Cap

US$50.5m

7D

10.5%

1Y

-72.3%

Updated

28 Mar, 2024

Data

Company Financials +

Cytosorbents Corporation

NasdaqCM:CTSO Stock Report

Market Cap: US$50.5m

CTSO Stock Overview

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally.

CTSO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Cytosorbents Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cytosorbents
Historical stock prices
Current Share PriceUS$0.95
52 Week HighUS$4.29
52 Week LowUS$0.84
Beta0.58
1 Month Change-1.04%
3 Month Change-14.41%
1 Year Change-72.30%
3 Year Change-89.20%
5 Year Change-87.37%
Change since IPO-97.83%

Recent News & Updates

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Recent updates

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13
Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

May 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 08
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents secures $4.3M contract by U.S. Department of Defense

Oct 06

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 03
We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Shareholder Returns

CTSOUS Medical EquipmentUS Market
7D10.5%2.2%0.4%
1Y-72.3%13.3%28.8%

Return vs Industry: CTSO underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: CTSO underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is CTSO's price volatile compared to industry and market?
CTSO volatility
CTSO Average Weekly Movement7.7%
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CTSO's share price has been volatile over the past 3 months.

Volatility Over Time: CTSO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997186Phil Chanhttps://www.cytosorbents.com

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.

Cytosorbents Corporation Fundamentals Summary

How do Cytosorbents's earnings and revenue compare to its market cap?
CTSO fundamental statistics
Market capUS$50.49m
Earnings (TTM)-US$28.51m
Revenue (TTM)US$36.35m

1.4x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTSO income statement (TTM)
RevenueUS$36.35m
Cost of RevenueUS$13.96m
Gross ProfitUS$22.39m
Other ExpensesUS$50.90m
Earnings-US$28.51m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.53
Gross Margin61.60%
Net Profit Margin-78.43%
Debt/Equity Ratio21.7%

How did CTSO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.